Status:
TERMINATED
Study Evaluating the Efficacy of DVS-233 in Fibromyalgia
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Fibromyalgia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to determine if DVS-233 is safe and effective in the treatment of pain and other symptoms of fibromyalgia syndrome.
Eligibility Criteria
Inclusion
- Fibromyalgia according to 1990 American College of Rheumatology (ACR) criteria
Exclusion
- Other painful conditions that may make results difficult to interpret.
- Treatment with other drugs for fibromyalgia with 14 days of study start or during the study.
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
End Date :
June 1 2007
Estimated Enrollment :
1050 Patients enrolled
Trial Details
Trial ID
NCT00301431
Start Date
August 1 2006
End Date
June 1 2007
Last Update
December 5 2007
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
Huntsville, Alabama, United States, 35801
2
Mobile, Alabama, United States, 36608
3
Phoenix, Arizona, United States, 85016
4
Anaheim, California, United States, 92801